Supernus Pharmaceuticals Ends UBS Credit Line Ahead of Indivior Combination

What happened

Supernus Pharmaceuticals ended its uncommitted, demand revolving credit line with UBS Bank USA on October 20, 2026, ahead of its planned combination with Indivior. No borrowings were outstanding, no early termination penalties applied, and UBS released its security interests in the collateral.

Confirmed

Global impact / market context

Closing a standby credit line before a merger simplifies the combined company's debt structure, since the new senior secured credit facility is expected to replace it. With nothing borrowed, Supernus avoids leftover obligations and termination costs, keeping its balance sheet cleaner for the Indivior combination.

Analyst inference

Companies preparing for mergers often clear old credit arrangements so the combined business starts with one coordinated facility. Because this line was uncommitted and undrawn, ending it carries little immediate cost, though investors may watch how the new senior secured credit facility, which is borrowed money secured by assets, is structured.

Analyst inference

What to watch

1. Supernus terminated the UBS line on October 20, 2026, and UBS released its security interests in the collateral, meaning its legal claims on pledged assets were removed. Confirmed
2. The combined company is expected to put in place a new senior secured credit facility, which means borrowed money backed by assets, and its size, cost and lenders are not yet disclosed. Proposed
3. Watch whether the Indivior combination closes as planned and whether the new credit facility is signed, since delays or changes in borrowing costs could alter the combined company's cash flexibility. Analyst inference

Evidence

• Original source link unavailable